H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Rapt Therapeutics (RAPT) to $27 from $6 and keeps a Buy rating on the shares following the 1-for-8 reverse stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT: